Caprock Group LLC raised its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 33.6% during the 2nd quarter, Holdings Channel.com reports. The fund owned 2,853 shares of the company’s stock after acquiring an additional 717 shares during the period. Caprock Group LLC’s holdings in IDEXX Laboratories were worth $1,390,000 as of its most recent SEC filing.
Several other large investors have also bought and sold shares of the stock. Riverview Trust Co purchased a new stake in shares of IDEXX Laboratories in the first quarter valued at about $26,000. Crewe Advisors LLC purchased a new stake in IDEXX Laboratories in the 1st quarter valued at about $26,000. Ridgewood Investments LLC bought a new position in shares of IDEXX Laboratories during the 2nd quarter worth approximately $27,000. Institutional & Family Asset Management LLC bought a new position in shares of IDEXX Laboratories during the 2nd quarter worth approximately $28,000. Finally, DSM Capital Partners LLC bought a new position in shares of IDEXX Laboratories in the fourth quarter valued at approximately $33,000. 87.84% of the stock is currently owned by institutional investors.
IDEXX Laboratories Price Performance
IDXX opened at $480.34 on Tuesday. The firm has a 50-day moving average price of $479.87 and a 200-day moving average price of $502.90. IDEXX Laboratories, Inc. has a twelve month low of $372.50 and a twelve month high of $583.39. The company has a quick ratio of 1.03, a current ratio of 1.37 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $39.54 billion, a price-to-earnings ratio of 46.50, a PEG ratio of 4.02 and a beta of 1.33.
Analysts Set New Price Targets
A number of analysts recently commented on IDXX shares. Stifel Nicolaus dropped their price target on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating on the stock in a report on Monday, June 24th. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. BTIG Research began coverage on shares of IDEXX Laboratories in a research report on Thursday, July 25th. They set a “buy” rating and a $580.00 price target for the company. Morgan Stanley decreased their price objective on shares of IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating for the company in a report on Tuesday, May 14th. Finally, Piper Sandler dropped their target price on shares of IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 14th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $582.25.
Check Out Our Latest Analysis on IDXX
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
See Also
- Five stocks we like better than IDEXX Laboratories
- What Are Dividend Champions? How to Invest in the Champions
- Why Block’s Key Components Make It a Solid Investment Choice
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Is Applied Digital’s Stock Set to Surge With NVIDIA’s Backing?
- What Does Downgrade Mean in Investing?
- 4 Reasons to Consider Adding General Mills to Your Portfolio
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.